bevacizumab + carboplatin + docetaxel + erlotinib

This is a combination regimen consisting of four agents—bevacizumab, carboplatin, docetaxel, and erlotinib—used in the treatment of non-small cell lung cancer (NSCLC). - **Bevacizumab** is a humanized monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), thereby preventing tumor blood vessel formation. - **Carboplatin** is a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis in rapidly dividing cells. - **Docetaxel** is a taxane-class chemotherapeutic that stabilizes microtubules and inhibits cell division. - **Erlotinib** is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that blocks EGFR signaling pathways involved in tumor proliferation. This combination has been studied as first-line or adjuvant therapy for patients with advanced or resected NSCLC, often followed by maintenance therapy with bevacizumab and erlotinib[1][2][6][8]. The regimen aims to target multiple pathways involved in cancer progression—angiogenesis, DNA replication/repair, mitosis, and EGFR-mediated signaling.